Risk factors for QTc-prolongation: systematic review of the evidence. - Wikidata - awgldk - TriplyDB

Risk factors for QTc-prolongation: systematic review of the evidence.

Risk factors for QTc-prolongation: systematic review of the evidence.

http://www.wikidata.org/entity/Q39052301

about

Development of a risk score for QTc-prolongation: the RISQ-PATH study.Humans Vary, So Cardiac Models Should Account for That Too!Pain medication and long QT syndrome.Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring.Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.Enhanced basal late sodium current appears to underlie the age-related prolongation of action potential duration in guinea pig ventricular myocytes.Predictive factors for clinically significant pharmacist interventions at hospital admission.Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer.Association between a frailty index based on common laboratory tests and QTc prolongation in older adults: the Rugao Longevity and Ageing Study.Cancer Pain Management: Opioid Analgesics, Part 2 Effect of serum electrolytes within normal ranges on QTc prolongation: a cross-sectional study in a Chinese rural general population

P2860

Q38915495-78EFAE2C-17CC-4074-B569-1CFEAC106CB4 Q42077295-EFB48F78-E4CD-4EF2-9BF9-781FCD0C4721 Q49422188-B4382541-2888-4F78-81E2-ED3C264110A6 Q50301186-CCA55B2F-9324-419C-A89B-9D66A6577CF4 Q50326000-79CBE003-1A69-4593-BD2D-B2EBA969CB8C Q51772816-1A3283D0-0134-4638-BB16-92448258CAC9 Q52681467-BC6D1FC8-D0AD-45FA-871D-9668D6ECCA46 Q55231435-34719658-6CEA-4738-9DA6-A5F8E49426BB Q55278779-5E5AB822-8B7A-42C0-8C69-6D023E96ABC4 Q55502584-8F45BA1A-2FB9-4F04-A537-DF30EB4F5501 Q57498749-14CABF78-7F52-4F82-B080-2D2AABC7BD0A Q58696795-0BA52CFF-2CD4-4F57-AD56-48AE2306698C

P2860

Risk factors for QTc-prolongation: systematic review of the evidence.

http://www.wikidata.org/entity/Q39052301

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Risk factors for QTc-prolongation: systematic review of the evidence.

@en

Risk factors for QTc-prolongation: systematic review of the evidence.

@nl

type

label

Risk factors for QTc-prolongation: systematic review of the evidence.

@en

Risk factors for QTc-prolongation: systematic review of the evidence.

@nl

prefLabel

Risk factors for QTc-prolongation: systematic review of the evidence.

@en

Risk factors for QTc-prolongation: systematic review of the evidence.

@nl

P1433

Q39052301-D15D6D72-5005-422B-9C34-970E87C6D5A8

P1476

Q39052301-A4303346-6086-4761-B8F0-E821D3779201

P2093

Q39052301-781542C9-8C5E-4520-80EC-594A56AE531A

Q39052301-D5202EAD-E4F2-4F09-B207-C88B5C66C2AE

P2860

Q39052301-221A51AA-C291-4617-9E34-93016BFD45B9

Q39052301-23665E71-F445-4365-85DF-23A92092A872

Q39052301-2A483344-C49D-44F1-88A2-378D6F37856E

Q39052301-2C18925B-02DA-4A69-B647-DF48B57B8A89

Q39052301-3057DAC0-7F1B-4A7B-9523-F75D043D804D

Q39052301-33D5493E-7E21-48D0-9929-651C26D7B6E7

Q39052301-3E95DC16-1768-485C-B41F-17F118FE9C64

Q39052301-56FB735E-1F4C-45FE-87C0-EBC0FCC74465

Q39052301-621CC6BB-089C-4283-9AF4-40C5D345E302

Q39052301-68D2E6A4-D078-42B3-B8C4-4D2EDA3514B1

P2888

Q39052301-904E4A87-BAD7-404B-86EA-6579CCCD44E0

P304

Q39052301-E4C3BD52-6A71-47E1-A443-650A7FEEB084

P31

Q39052301-7307A919-C3B3-4340-987B-7327C86C4750

Q39052301-835c67f0-7082-49c8-9b62-7c0c2c996b5c

P356

Q39052301-1B4C9664-B948-4482-ABB8-6F2B2E00737D

P433

Q39052301-71C525E2-D64B-4901-9600-C3C5DD7533EF

P478

Q39052301-3E60B061-1410-4052-B020-82C9E51BDD7B

P50

Q39052301-2CF9E059-CB1B-4059-91D3-5AA1AED1E6E6

Q39052301-76846802-F889-4783-8977-FB18DCDA6707

Q39052301-96CB0D8D-56D7-40C4-97DD-FB30AE7905EA

P577

Q39052301-4BB0F009-56C5-4BE3-B139-301215829D40

P698

Q39052301-753BD79C-544C-46DE-8A6C-F9A657DFF644

P356

S11096-016-0414-2

P1433

International journal of clinical pharmacy

P1476

Risk factors for QTc-prolongation: systematic review of the evidence.

@en

P2093

Joris Vandenberghe

http://www.w3.org/2001/XMLSchema#string

Veerle Foulon

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

QT interval and antidepressant use: a cross sectional study of electronic health records

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Drug- and non-drug-associated QT interval prolongation.

Drug-induced prolongation of the QT interval.

Mechanisms of drug induced QT interval prolongation.

Drug-induced QT interval prolongation: mechanisms and clinical management

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

QTc prolongation, torsades de pointes, and psychotropic medications.

P2888

s11096-016-0414-2

P304

16-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11096-016-0414-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Bert Vandenberk

P577

2016-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28012118

http://www.w3.org/2001/XMLSchema#string